EyePoint Pharmaceuticals AI Stock Analysis
EyePoint Pharmaceuticals (PV3B) AI Stock Analysis
EyePoint Pharmaceuticals
(XETRA:PV3B)
No summary available
EyePoint Pharmaceuticals (PV3B) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 30.95M
- Dividend Yield
- ―
- Average Volume (3M)
- 995
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 1.57
- Revenue Growth
- -94.40%
- EPS Growth
- -26.64%
- Country
- Germany
- Employees
- 214
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
EyePoint Pharmaceuticals Business Overview & Revenue Model
Company Description
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product p...
EyePoint Pharmaceuticals Earnings Call Summary
The call conveyed significant disappointment following the failure of both Phase III wet AMD trials and the resulting program discontinuation and workforce reduction. However, management expressed confidence in DURAVYU's DME opportunity, supported by the VERONA data, the drug's multi-mechanism rationale, extensive safety experience, ongoing COMO and CAPRI studies, and planned cost reductions. The outlook was mixed, with meaningful clinical and financial execution risks balanced by a focused DME strategy and several stated efficacy and durability advantages.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
EyePoint expects approximately $118 million in cash, cash equivalents and investments and marketable securities at September 30, 2026, to fund operations into late Q3 2027, excluding any potential cash flows from business development or financing activities that we may undertake or other operational savings and adjustments presently under active review; it announced a workforce reduction of approximately 53%, generating $30 million in annualized savings once fully implemented. COMO and CAPRI enrolled over 550 patients, with top line results expected early in the fourth quarter of 2027 and planned to be reported simultaneously; the primary endpoint is BCVA from baseline to week 52 to 56. The amended supplement-injection criteria allow supplementation for a decline of BCVA greater than five letters from [ VESTO ] study associated on the same visit with an increase in CST of 50 microns or more, compared with the prior threshold of a decline of 10 letters associated with an increase in CST of 50 microns. EyePoint expects to have greater than 300 patients with two years of data at the end of the DME trial, should they be positive, which should we expect, if positive, give us a label for reinjection indefinitely.
EyePoint Pharmaceuticals Risk Analysis
EyePoint Pharmaceuticals disclosed 58 risk factors in its most recent earnings report. EyePoint Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksEyePoint Pharmaceuticals Peers Comparison
Overall Rating
MGTX53Neutral
RGNX51Neutral
OCGN45Neutral
EDIT39Underperform
OCS38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 53Neutral | $813.12M | 9.79 | 85.38% | ― | 1365.90% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | $480.05M | -2.26 | -203.98% | ― | -4.59% | 8.03% | |
| 45Neutral | $250.82M | -3.75 | 643.95% | ― | -11.01% | 8.03% | |
| 39Underperform | $273.18M | -2.87 | -130.43% | ― | 7.43% | 74.00% | |
| 38Underperform | $456.20M | -4.51 | -39.51% | ― | ― | 31.72% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:PV3B | Eyepoint Pharma | 0.25 | -11.29 | -97.82% | |
| OCGN | Ocugen Inc | 0.74 | -0.42 | -36.29% | |
| RGNX | RegenXBio Inc. | 7.26 | -4.54 | -38.47% | |
| EDIT | Editas Medicine Inc. | 1.77 | -0.65 | -26.86% | |
| MGTX | Meiragtx Holdings | 8.32 | 0.86 | 11.53% | |
| OCS | Oculis Holding Ag | 7.39 | -11.87 | -61.63% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
